The first survivor also remained in need of thyroid and growth hormone substitution and continued to suffer from obsessive compulsive disorder with comorbid depression, severe fatigue, and arthralgia as well as impairment in NCF at baseline line and follow-up assessment. The gene discussed is GH1; the disease is depressive symptom measurement.